Department of Ophthalmology, Second University of Naples, Naples, Italy.
Retina. 2013 Feb;33(2):397-402. doi: 10.1097/IAE.0b013e318261a73c.
To report the morphologic and functional outcomes resulting from the use of intravitreal pegaptanib (IVP) sodium (Macugen) in patients with myopic choroidal neovascularization.
An open-label, nonrandomized, prospective clinical trial was performed. Morphologic outcome, such as foveal thickness, was assessed by optical coherence tomography, whereas functional outcomes were assessed by best-corrected visual acuity and microperimetry. Treatment protocol consisted of 3 consecutive IVP (0.3 mg/0.05 mL; baseline, 6th week, and 12th week). Follow-up checks were scheduled at the following intervals: baseline, 18, 24, 36, and 48 weeks.
Twenty eyes from 20 patients were studied. All patients completed follow-up at 48 weeks. After IVP, a significant decrease in foveal thickness occurred (-20%), and at the end of follow-up, choroidal neovascularization closure was obtained in all eyes. An improvement of functional parameters was recorded in all patients (best-corrected visual acuity from 25.5 ± 8.09 letters to 45.5 ± 8.16 letters, P < 0.0001; microperimetry from 8.40 ± 2.14 dB to 10.8 ± 2.05 dB, P < 0.01). The mean number of IVP was 3, and none of patients met the re-treatment criterion during the entire follow-up period. Neither ocular nor systemic side effects were observed.
The findings demonstrate that the selective inhibition of VEGF-165 isoform by IVP is an effective treatment for myopic choroidal neovascularization.
报告使用玻璃体内注射培加他尼钠（Macugen）治疗近视性脉络膜新生血管的形态和功能结果。
进行了一项开放标签、非随机、前瞻性临床试验。通过光学相干断层扫描评估形态学结果，如中心凹厚度，而通过最佳矫正视力和微视野计评估功能结果。治疗方案包括 3 次连续玻璃体内注射（0.3mg/0.05ml；基线、第 6 周和第 12 周）。随访检查安排在以下时间间隔进行：基线、18、24、36 和 48 周。
20 名患者的 20 只眼进行了研究。所有患者均在 48 周时完成随访。玻璃体内注射后，中心凹厚度显著下降（-20%），在随访结束时，所有眼睛均获得脉络膜新生血管闭合。所有患者的功能参数均得到改善（最佳矫正视力从 25.5±8.09 个字母提高到 45.5±8.16 个字母，P<0.0001；微视野从 8.40±2.14dB 提高到 10.8±2.05dB，P<0.01）。玻璃体内注射的平均次数为 3 次，在整个随访期间，没有患者符合再次治疗的标准。未观察到眼或全身副作用。
这些发现表明，玻璃体内注射培加他尼钠选择性抑制 VEGF-165 同工型是治疗近视性脉络膜新生血管的有效方法。
